Remdesivir was granted Emergency Use for severely ill patients, so I don't think that in this upcoming week we are comparing apples to apples in any case. I think that Leronlimab will be the first therapeutic to prove efficacy for mild to moderately ill patients. Obviously we would expect to see a much better number than 11 days in our m to m trial, since m to m patients are less ill than severe patients.